Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
Lung function: FEV1 mL (change from baseline) · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 600 participantsModerate
Findings
What do systematic reviews say?
37 questions · 37 findings · 2 reviews
No studies found 4 · 10.8%GRADE not reported 0 · 0%Very low 12 · 32.4%Low 10 · 27%Moderate 11 · 29.7%High 0 · 0%
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
FEV1 % predicted: absolute change from baseline · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 600 participantsModerate
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
FVC · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 600 participantsModerate
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
Lung function: FEF25‐75 mL/s (change from baseline) · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 600 participantsModerate
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 600 participantsModerate
Summary of findings ‐ Inhaled mannitol vs dornase alfa
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young adults with CF
1 finding from 1 review
- no estimate extracted231 participantsVery low
Summary of findings ‐ Inhaled mannitol vs dornase alfa
Lung function: FEV1 mL (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FEV1 mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
- MD 2.8231 participantsVery low
Summary of findings ‐ Inhaled mannitol vs dornase alfa
FEV1 % predicted · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ Inhaled mannitol vs dornase alfa
FVC · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
- MD 0.14231 participantsVery low
Summary of findings ‐ Inhaled mannitol vs dornase alfa
Lung function: FEF25‐75 mL/s (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FEF25-75 mL/s (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
- no estimate extracted231 participantsVery low
Summary of findings ‐ Inhaled mannitol vs dornase alfa
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
- no estimate extracted231 participantsVery low
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young adults with CF
1 finding from 1 review
- no estimate extracted231 participantsVery low
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa
Lung function: FEV1 mL (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEV1mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
- no estimate extracted231 participantsVery low
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa
FEV1 % predicted · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa
FVC · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
- no estimate extracted231 participantsVery low
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa
Lung function: FEF25‐75 mL/s (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol plus dornase alfa changes lung function: FEF25-75 mL/s (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
- no estimate extracted231 participantsVery low
Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
- no estimate extracted231 participantsVery low